GeoVax Labs, Inc. Announces Six Month 2009 Financial Results and Provides Operatio...(ense and commercialize human vaccines fo...),Health

Date:8/7/2009

ense and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become infected. GeoVax AIDS vaccines also may be effective as therapeutics (treatment of people already infected with AIDS virus).

GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax's AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $17 million IPCAVD grant awarded in late 2007.

Safe Harbor Statement

All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can d
'/>"/>

SOURCE GeoVax Labs, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. GeoVax Co-Founder Dr. Harriet Robinson Named 2007 AAAS Fellow
2. Nortech Labs, Inc. and MEDNET(TM) Make for a Notable, Natural Partnership
3. Scarguard Labs, LLC Appoints Richard E. Pino as CFO
4. Scarguard Labs, LLC Expands Distribution Reach Through Agreements With McKesson Drugs and Publix Supermarkets
5. Innovatech Labs, Assisting Companies in Adhering to Halogen-Free Manufacturing Standards Aimed at Protecting the Environment
6. ForSight Labs, LLC Announces Formation of Its Third Company, ForSight VISION3, Inc. and Closing of $6 Million in Series A Funding
7. NATB Announces Partnership With Ronald McDonald House Charities(R)
8. LCA Announces More Requests for Bids on Lung Cancer Research Programs Funded Through the Department of Defense
9. ThermoGenesis Announces Launch of Res-Q System; New Device Expands Companys Presence in Bone Marrow Sector
10. Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results
11. AMN Healthcare Announces Second Quarter 2009 Results